References
MARTIN S, et al. The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the U.S. 74th Annual Scientific Sessions of the American Diabetes Association : abstr. 1190-P, 13 Jun 2014.
NESLUSAN C, et al. Cost-Effectiveness Analysis of Canagliflozin (CANA) vs. Maximally Titrated Glimepiride (GLIM) as an Add-on to Metformin (MET) in Patients with Type 2 Diabetes Mellitus (T2DM) in the United States. 74th Annual Scientific Sessions of the American Diabetes Association : abstr. 1189-P, 13 Jun 2014.
Rights and permissions
About this article
Cite this article
Canagliflozin is canny add-on to metformin in US. PharmacoEcon Outcomes News 709, 4 (2014). https://doi.org/10.1007/s40274-014-1449-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1449-z